In another retrospective study on patients with advanced NSCLC progressed during immunotherapy, presence of mutations in the KRAS and serine/threonine kinase 11 (STK11) genes was specifically identified in the cohort of patients with hyperprogression (26). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.